Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
9
×
clinical trials
life sciences
national blog main
archive
boston
boston blog main
boston top stories
alnylam pharmaceuticals
medical
patisiran
recalls
rna interference
safety
alexion pharmaceuticals
biotech
deals
drugs
hereditary transthyretin amyloidosis
national top stories
onpattro
san francisco blog main
san francisco top stories
acute hepatic porphyrias
akcea therapeutics
akin akinc
aminolevulinic acid
amyotrophic lateral sclerosis (als)
andrew fire
autoimmune disorders
boehringer ingelheim
cannabidiol
complement system
craig mello
dicerna pharamceuticals
dravet syndrome
epidiolex
fen-phen
fenfluramine
generalized myasthenia gravis
What
drug
9
×
pharmaceuticals
9
×
fda
recall
medication
medicine
recalled
acella
ago
alnylam
announced
approved
blood
consumers
disease
high
medicines
pharma
popular
potent
pressure
rnai
thyroid
weeks
according
advised
afternoon
alembic
alerted
alnylam’s
alternative
approval
aren’t
assuming
autoimmune
battle
bottles
cancer
candidate
cannabis
Language
unset
Current search:
fda
×
drug
×
pharmaceuticals
×
@slashgear.com
3 years ago
Popular thyroid drug recalled because the pills aren’t potent enough
@slashgear.com
3 years ago
High blood pressure drug recalled because labels were mixed up
@slashgear.com
3 years ago
Popular thyroid drug recalled because it’s ‘super potent’ says FDA
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@slashgear.com
4 years ago
High blood pressure drug recall expands again over cancer risk
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug